Natomas Messenger

Founded 2009

 

Serving North & South Natomas & Sacramento County
 
  Home Community Finance Employment Your Home Your Money Your Kids Your Health  
  Business Education Politics Police & Fire Veterans' News Real Estate Consumer News Taxes  
  Church Food Recipes Gardening Car Care Fashion Beauty Pets  
  Lifestyles Sports Feature Writers Entertainment Environment Human Interest Technology Travel  

Your "Local Sunday Newspaper" Seven Days a Week!

Omaha Steaks Webroot Software Inc.
California Job Journal
Natomas Messenger and Rainbow Rewards
In Association with Amazon.com


Your Health

FDA Approves JUVÉDERM® XC, The Latest Advancement In Hyaluronic Acid Dermal Fillers From Allergan, Inc., For A More Comfortable Injection Experience

Posted: 6/9/2010

FDA Approves JUVÉDERM XC

(NAPSA) - There’s encouraging news for anyone looking to instantly smooth the wrinkles around the nose and mouth but is concerned about pain. Now available nationwide, JUVÉDERM® XC from Allergan, Inc. contains li - docaine for enhanced comfort during treatment of the “parentheses” lines between the nose and mouth.

“The ‘no pain, no gain’ mentality has definitely played a role in the way women over the years have thought about aesthetic treatments. However, that is changing with recent advancements in aesthetic medicine,” said Amy Wechsler, M.D., board-certified dermatologist and psychiatrist. “In the clinical trial leading up to the U.S. Food and Drug Administration (FDA) approval of JUVÉDERM® XC, 93 percent of patients reported less pain when treated with JUVÉDERM® XC compared to the non-lidocaine JUVÉ- DERM® formulation1. Patients can now receive the same smooth results as demonstrated with JUVÉDERM® but enjoy a more comfortable injection experience.”

JUVÉDERM® XC with 0.3 percent lidocaine numbs the treatment area within seconds, po - tentially reducing the need for an additional anesthetic. Before the introduction of JUVÉDERM® XC, it often took up to 30 minutes for an anesthetic block to take effect. The new formulation provides the same smooth, longlasting results as demonstrated with existing formulations of JUVÉDERM® and now of fers a more comfortable treatment experience and potentially less time spent in the physician’s office compared to the non-lidocaine JUVÉDERM® formulation.

“JUVÉDERM® is the first and only hyaluronic acid dermal filler approved by the FDA to last up to one year from initial treatment2,” said Dr. Wechsler. “My patients are satisfied with treatment results, and JUVÉDERM® has steadily gained popularity since its introduction.”

For more information about JUVÉDERM® dermal fillers and to find a local physician, please visit www.Juvederm.com and become a fan of the official JUVÉDERM® Facebook page.

Funnies Extra
Pay Legal Ads Online
Messenger Publishing Group

Advertise With Us
About Natomas Messenger
Classified Advertising
Letters to the Editor
Previous Issues

Front Page Sports
MBK Homes

Legal Advertising Hotline
Call Dan Direct at
916-532-2113
dan@carmichaeltimes.com
Legal Advertising Rates

 



Top Stories
 

California News
 



About The Natomas Messenger | Copyright Notice
The Natomas Messenger | Paul V. Scholl, Publisher
Mailing Address: 7405 Greenback Lane, #129 | Citrus Heights, CA 95610-5603
Email: publisher@NatomasMessenger.com | Site Designed and Hosted by TheSiteBarn.com

View PDF files of Back Issues